EmailHospital Circular 01/2006
Date Issued: 20 January 2005
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 February 2006.
We have had recent advice from the Commonwealth Government of changes to the Highly Specialised Drugs Program, effective 1 February 2006.
ADDED DRUGS
Tenofovir disoproxil fumarate with emtricitabine
Treatment of HIV infection in patients with:
- CD4 cell counts of less than 500 per cubic millimetre; or
- viral load of greater than 10,000 copies per mL.
| 6468K | Tablet 300 mg - 200 mg | 30 | $781.00 | Truvada | GI |
Thalidomide
CAUTION:
Thalidomide is a category X drug and must not be given to pregnant women. Pregnancy in female patients or in the partners of male patients must be avoided during treatment and for 1 month after cessation of treatment.
Relapsed or refractory multiple myeloma in patients who have failed at least 1 other treatment.
NOTE:
Patients receiving thalidomide under the PBS listing must be registered in the Pharmion Risk Management Program.
| 6469L | Capsule 50 mg | 28 | $420.00 | Thalidomide Pharmion |
PI |
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Lea Pope
Acting Director, Programs
Metropolitan Health & Aged Care Services
